A few days after a similar announcement from GlaxoSmithKline, Sanofi said it plans to scale up its presence in Africa, looking to invest in marketing and R&D in response to the market's continued growth.
Sanofi is on the lookout for acquisitions to boost key business units, such as consumer and animal health products, and expects strong growth in the "strategic continent" of Africa, its chief executive told Reuters on Wednesday.
PARIS (dpa-AFX) - Sanofi Pasteur, the vaccines division of Sanofi (SNY),
announced the U.S. FDA has expanded the approved age indication of Adacel
(Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
Adsorbed; Tdap) for...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+SNY%29%2C+Regeneron+%28REGN%29+Reports+Alirocumab+Phase+2+Met+Primary+Endpoint+in+Japanese+Patients/9336530.html for the full story.
PARIS (dpa-AFX) - French drug maker Sanofi (SNYNF.PK, SNY) Monday announced
the appointment of Anne Beal to the newly created position of Chief Patient
Beal is a pediatrician and public health specialist. She joins Sanofi from...
a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the Food
and Drug Administration (FDA) approved revised prescribing information
for the use of Thyrogen® (thyrotropin alfa for injection) to
After 20 years in the lab and $1.4 billion in R&D costs, Sanofi's in-development dengue fever vaccine is on the verge of regulatory applications, and, despite a few clinical hiccups, the drugmaker told Reuters it believes it has a blockbuster on...